Drug Profile
Sacubitril/valsartan - Novartis
Alternative Names: AHU-377/valsartan; dapagliflozin - Novartis; Enrest; Enresuto; Entresto; ENTRESTO SPRINKLE; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitrilLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Rovi
- Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Cardiovascular therapies; Erectile dysfunction therapies; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles; Urologics
- Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Essential hypertension; Heart failure; Hypertension
- Phase III Erectile dysfunction; Kidney disorders
- Phase II Hypertrophic cardiomyopathy
Most Recent Events
- 12 Apr 2024 Registered for Heart failure (In adolescents, In children, In infants) in USA (PO)
- 01 Feb 2024 Novartis plans a phase III trial for Hypertension (Treatment naïve, Monotherapy, Combination therapy) (PO, Tablet) (NCT06236061)
- 29 Dec 2023 Novartis completes phase III trial in Heart failure (In infants, In children, In adolescents) in USA, Argentina, Austria, Bulgaria, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, South Korea, Lebanon, Poland, Portugal, Russia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand and Turkey (PO, Tablet, Capsule, Liquid) (NCT03785405)